1. In Vivo
  2. >>Global Vision

Near-Term BioPharma Profitability: Must-Have or Distraction?

 
• By Melanie Senior

Being profitable has its advantages, particularly in the current biopharma funding environment-and particularly for those companies able to leverage relatively small investment into relatively quick profitability. But for firms whose own pipelines have yet to come to fruition, it also imposes constraints and pressures on management that wouldn't otherwise be there. In Vivo Europe Rx looks at how four of Europe's biopharma firms became profitable, and how this has affected company strategy. Their differences lie precisely in the purpose of their early profits-as a means to an end, or as the end in itself.

Sustainable profitability is the ultimate aim of any business. And given the recent, extended downturn in the financial markets, getting to profitability faster—before the fruits of a discovery-based pipeline can be harvested—seems more sensible than ever. In Europe, acquisition is the preferred, though not the only, method for jump-starting profits—using relatively high-value biotech shares to buy a troubled business with at least the potential for making money sooner than can its acquirer.

Early-profit strategies, broadly speaking, have served the four companies we profile in this issue, along with a few other European...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.